News & Events: 2011

InteRNA Technologies announces establishment of Supervisory Board

November 21, 2011
Nijmegen/Utrecht (the Netherlands) - November 21, 2011 - InteRNA Technologies B.V., a drug discovery and development company engaged in the development of microRNA-based therapeutics for oncology, announces...
Read more

ORCA Therapeutics receives up to € 5 Million Innovation Credit from Dutch Government

November 08, 2011
Amsterdam, The Netherlands - November 8th, 2011 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announces today that it has received an innovation cr...
Read more

InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways

November 02, 2011
Utrecht (the Netherlands) - InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer. Und...
Read more

ISA Pharmaceuticals strengthens its Supervisory Board with the appointment of Professor Jan van de Winkel

October 17, 2011
Leiden, The Netherlands, October 17th, 2011 - ISA Pharmaceuticals, a leader in the development of novel immunotherapeutic products for oncology and infectious diseases, today announced that Professor Jan van...
Read more

FDA grants ISA Pharmaceuticals Orphan Drug Designation for the treatment of Vulvar Intraepithelial Neoplasia with its lead product ISA-HPV-SLP®

October 05, 2011
Leiden, The Netherlands, October 5th , 2011 ISA Pharmaceuticals BV, a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that orphan drug designati...
Read more

Merus launches MeMo™, a transgenic mouse for improved therapeutic human monoclonal antibodies

September 27, 2011
Utrecht, The Netherlands, September 27, 2011 - Merus announced today that it has completed the construction of a single-light chain transgenic mouse for the generation of therapeutic human monoclonal antibod...
Read more

Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics

September 12, 2011
Collaboration to investigate potential of AtuPLEX™ in the development of novel microRNA therapeutics targeting cancer London, UK & Nijmegen/Utrecht, Netherlands, September 12, 2011 - Silence Therapeutics pl...
Read more

SomantiX announces establishment of Scientific Advisory Board

July 07, 2011
Amsterdam (the Netherlands) - July 7, 2011 - SomantiX B.V., a biotech company focused on the development of new angiogenesis inhibitors, announces the establishment of its Scientific Advisory Board. Tumor...
Read more

ORCA Therapeutics announces Grant of European Patent covering its proprietary T1 oncolytic adenovirus technology

July 04, 2011
Amsterdam, The Netherlands - July 4th, 2011 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announces today that it has secured key intellectual prop...
Read more

Aglaia announces sale of portfolio company Syntarga

June 23, 2011
Bilthoven, June 23, 2011 - Aglaia Oncology Fund is pleased to announce the acquisition of its portfolio company Syntarga B.V. b...
Read more
Aglaia announces sale of portfolio company Syntarga

ISA Pharmaceuticals closes a License Agreement with Transgene aimed at the development of novel vaccines for TB

May 26, 2011
Leiden, The Netherlands, May 26th, 2011 - ISA Pharmaceuticals B.V., a private, clinical stage company and leader in the development of immunotherapeutic products for oncology and infectious diseases, and Tra...
Read more

Merus and ChromaCon receive a € 1.8 million project grant for the discovery and development of bispecific antibodies for therapy of advanced breast cancer

May 16, 2011
Utrecht, The Netherlands and Zurich, Switzerland, May 16 2011 - Merus BV and ChromaCon AG announced today the award of a EUREKA Eurostars grant with a total budget of €1.8 million to discover and develop bis...
Read more

ISA Pharmaceuticals and Prosensa receive Mibiton funding for peptide manufacturing facility

May 12, 2011
Leiden, The Netherlands, April 26th , 2011 - ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that Mibiton supports IS...
Read more

InteRNA Technologies Strengthens its R&D Team

April 29, 2011
Nijmegen/Utrecht, The Netherlands, April 29th, 2011 - InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, is pleased to announce...
Read more

ISA Pharmaceuticals embarks on EUR 4 million Cancer Vaccine development track awarded by CTMM

March 22, 2011
ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, announced that CTMM, an agency of the Dutch Ministry of Economic Affairs, has awarded...
Read more

Merus receives € 0.75 million grant for the discovery and development of Oligoclonics™ antibody therapy for colon cancer.

January 05, 2011
Utrecht, The Netherlands, January 5th 2010 ‐ Merus announced today that it has received a € 0.75 million grant for the discovery and development of an antibody combination therapy for colon cancer using its...
Read more

Home > News & Events > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds